两党强烈支持在具有代表性的美国样本中将受控迷幻药用作治疗或增强疗效:公共政策仍需谨慎

Q1 Neuroscience
AJOB Neuroscience Pub Date : 2024-04-01 Epub Date: 2024-02-05 DOI:10.1080/21507740.2024.2303154
Julian D Sandbrink, Kyle Johnson, Maureen Gill, David B Yaden, Julian Savulescu, Ivar R Hannikainen, Brian D Earp
{"title":"两党强烈支持在具有代表性的美国样本中将受控迷幻药用作治疗或增强疗效:公共政策仍需谨慎","authors":"Julian D Sandbrink, Kyle Johnson, Maureen Gill, David B Yaden, Julian Savulescu, Ivar R Hannikainen, Brian D Earp","doi":"10.1080/21507740.2024.2303154","DOIUrl":null,"url":null,"abstract":"<p><p>The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.</p>","PeriodicalId":39022,"journal":{"name":"AJOB Neuroscience","volume":" ","pages":"82-89"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists.\",\"authors\":\"Julian D Sandbrink, Kyle Johnson, Maureen Gill, David B Yaden, Julian Savulescu, Ivar R Hannikainen, Brian D Earp\",\"doi\":\"10.1080/21507740.2024.2303154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.</p>\",\"PeriodicalId\":39022,\"journal\":{\"name\":\"AJOB Neuroscience\",\"volume\":\" \",\"pages\":\"82-89\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJOB Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21507740.2024.2303154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJOB Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21507740.2024.2303154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 0

摘要

迷幻药迷幻药已显示出治疗精神疾病和改善健康人福祉的前景。在一些司法管辖区(如美国俄勒冈州),已经允许或即将允许将迷幻药用于这两种用途,然而公众对这种转变的态度却没有得到充分研究。我们对具有全国代表性的 795 名美国人进行了抽样调查,以评估在获得适当许可的情况下使用迷幻剂治疗精神疾病或提高幸福感的道德状况。在这两种情况下,参与者都认为个人的决定在道德上是积极的,这显示了两党的强烈支持。考虑到在创新监管模式下公众的强烈态度,这些结果可以为有关监管下使用迷幻药的有效决策提供信息。我们没有探讨在无监督或无许可的社区或社会环境中使用迷幻剂的态度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists.

The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AJOB Neuroscience
AJOB Neuroscience Neuroscience-Neuroscience (all)
CiteScore
12.20
自引率
0.00%
发文量
48
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信